CaseCare360: Advanced Melanoma – Key Decision Points in Immune Checkpoint Inhibitor Therapy

CaseCare360: Advanced Melanoma – Key Decision Points in Immune Checkpoint Inhibitor Therapy is organized by Healio,Vindico Medical Education.

This enduring material is approved for 1 year from the date of original release, September 30, 2025, to September 29, 2026.

Description:
Despite significant advances in the treatment of advanced melanoma with ICIs, challenges remain in tailoring therapy based on the latest clinical evidence. This CaseCare360 guides oncologists and advanced practice providers through key decision points along the melanoma disease course, emphasizing the importance of shared decision-making. Using a simulated patient journey, participants will review evidence-based strategies for individualizing use of ICIs, including subcutaneous anti–programmed cell death protein 1 (PD-1) options. Faculty will highlight best practices for adjuvant treatment after resection, selecting combination regimens for advanced disease, and monitoring and managing immune-related adverse events to optimize long-term outcomes and quality of life.

Learning Objectives:
Upon successful completion of this activity, participants should be better able to:

• Individualize the use of immunotherapy for patients with advanced melanoma based on the latest evidence and patient preferences.
• Utilize subcutaneous formulations of anti–PD-1 therapy in patients who may benefit.
• Implement effective approaches to monitor and manage immune-related adverse events associated with ICIs.